Thomas E. Stinchcombe on Muck Rack

Thomas E. Stinchcombe

Chapel Hill
As seen in: Nature, The Oncologist, Therapeutic Advances in Medical Oncology, SAGE Publishing, JAMA Oncology, JAMA: Journal of the American Medical Association, Medscape, MDedge Hematology and Oncology, Journal of Clinical Oncology, Journal of Global Oncology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Thomas E.

Contact Thomas E., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer : A Randomized Clinical Trial

|
By Jamie E. Chaft, Zhuoxin Sun, Charles M. Rudin, Charles Simone, Kurt R. Oettel, David Kozono, Rajitha Sunkara, Bryan Faller, James M. Isbell, Vladimir Hugec, Jeffrey M. Clarke, Ramaswamy Govindan, Jacob Sands, John Heymach, Luis E Raez, Shakun Malik, Thomas E. Stinchcombe, Sumithra J. Mandrekar, Jeffrey Bradley, David E. Gerber, Everett E Vokes, David Gandara, Charles Staley, Suresh S. Ramalingam, Onkar V. Khullar, Asheesh Shipstone, Eric C. McGary, Ashita Talsania
| JAMA: Journal of the American Medical Association Verified
Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer: A Randomized Clinical Trial Supplement 1. Supplement 2. eFigure 1. Disease-free survival sensitivity analysis excluding new primary lung cancers eFigure 2. Disease-free survival in patients with negative and low tumoral PD-L1 eTable 1. Grade 3-5 Treatment-related Toxicities per CTCAE v4.0 eTable 2. Treatment-related Grade 3-5 Events Occurring in ≥ 1% of patients (n,%) Supplement 3.
Open in Who Shared Issue with article?

Neoadjuvant Osimertinib: A Step Ahead or Just a Step?

|
By Thomas E. Stinchcombe
| Journal of Clinical Oncology Verified
1; over the past two decades, nearly a dozen molecular targets have been successfully targeted to achieve therapeutic gains for patients. Tyrosine kinase inhibitors (TKIs) with a higher selectivity to mutant receptors over the wild-type receptors confer a significant improvement in patient outcomes with relatively modest toxicity for several molecular targets in lung adenocarcinoma.
Open in Who Shared Issue with article?

Early-Phase Trials in Journal of Clinical Oncology

|
By Thomas E. Stinchcombe, Charles Craddock, Andrew H. Ko
| Journal of Clinical Oncology Verified
Journal of Clinical Oncology (JCO).1 Previously, phase I trials were straightforward investigations of a novel agent to define the maximum tolerated dose and schedule and to assess acute adverse events.
Open in Who Shared Issue with article?
See all 28 licensed articles (34 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified